• Led efforts to redesign immunoassay for the detection of anti-Coccidioides antibodies in canine and feline serum samples•Led the development of IVD assays for the detection of Histoplasmosis in human samples• Successfully optimized commercially available interferon gamma detection assay • Worked with a diverse team to develop risk assessment materials for lateral flow assays in accordance to ISO 14971:2019

• Led the development of Crystal Diagnostics’ Salmonella detection assaysCDx’s first assay with AOAC validations in five matrices and validated confirmation procedures• Led the development of the second-generation Salmonella detection assay• Led the redesign of negative control microspheres for an immunomagnetic separation and liquid crystal-based assay• Led Crystal Diagnostics’ development effort for detection of pathogens in cannabis• Part of a team that completed AOAC accreditation of E. coli O157 and STEC detection in food matrices and Listeria monocytogenes on surface swabs• Supported CDx’s engineering department to improve instrumentation and consumables• Trained multiple customers on the use of Crystal Diagnostics’ assays and instruments• Assisted sales staff during customer interactions

• Led group responsible for all microbiological activities for the company• Directed projects that launched more than 13 new antibacterial products, including the first commercially available, purified polyclonal antibodies against the “Big Six” E. coli STEC strains• Trained and supervised an R&D Associate for nearly 2 years• Developed kinetic ELISA to screen purified antibodies for cross-reactivity• Developed a biosensor assay against bacterial targets utilizing biolayer interferometry and presented the data in three invited talks• Led collaboration efforts with customers for a flow cytometry based bacterial detection system• Established the company’s first anaerobic chamber for the growth of oxygen sensitive microorganisms • Closely involved in building business relationships with new clients• Established and improved production documents as engineering controls supporting the ISO 9001 quality management system • Participated in Sales and Marketing Team activities, including distributor and customer training

•Studied the effects of bile-salts on Salmonella invasion using transcriptional fusions and qRT-PCR to monitor gene expression in presence or absence of bile•Utilized lambda gt-11 derivative bacteriophage to create prototype vaccine protective against Salmonella Typhi and Mycobacterium tuberculosis•Trained three first year graduate students during their respective rotations

RAPID MODE OF ACTION GROUP:•Tested model organisms in MIC assays against a library of various compounds•Determined mode of action of library compounds via sequencing of mutated organisms•Maintained cultures and frozen stocks of various organisms and putative mutantsNATURAL PRODUCTS GROUP: •Lead technician responsible for high-throughput isolation of >10,000 mutated Saccharopolyspora pogona colonies•Responsible for cataloging, organizing, and maintenance of frozen cultures of desired mutants•Developed molecular microbiology skills by conjugating desired genes from Saccharopolyspora pogona into production strain of Saccharopolyspora spinosaTRAIT DEVELOPMENT GROUP: •Gained extensive molecular biology experience by routinely isolating genomic DNA from various transgenic plants•Analyzed plant genomic DNA, via Southern blot, to determine transgene presence and copy number